Phio Pharmaceuticals(US:PHIO) Newsfile·2025-09-23 11:45Core Viewpoint - Phio Pharmaceuticals is advancing its proprietary INTASYL® gene silencing technology aimed at treating skin cancers, with positive interim results reported from an ongoing Phase 1b clinical trial for its lead compound PH-762 [1][4]. Group 1: Company Overview - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on immuno-oncology therapeutics [4]. - The company's lead clinical program, PH-762, targets the PD-1 gene associated with various skin cancers, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [4]. Group 2: Clinical Trial Progress - The ongoing Phase 1b dose escalation clinical trial for PH-762 has shown positive interim safety and efficacy results [1]. - PH-762 is being evaluated as a potential non-surgical treatment option for skin cancers [4]. Group 3: Upcoming Events - Phio Pharmaceuticals will participate in a live virtual non-deal roadshow hosted by Renmark Financial Communications on September 30, 2025, where CEO Robert Bitterman will present updates on the company's technology and clinical progress [2][3].